Challenges, Considerations, and Principles to Guide Trials of Combination Therapies for Chronic Hepatitis B Virus

被引：12
作者：
Anderson, Ryan Taylor [1 ]
Lim, Seng Gee [2 ]
Mishra, Poonam [3 ]
Josephson, Filip [4 ]
Donaldson, Eric [3 ]
Given, Bruce [5 ]
Miller, Veronica [1 ]
机构：
[1] Univ Calif Berkeley, Washington, DC 20036 USA
[2] Natl Univ Singapore, Singapore, Singapore
[3] US FDA, Silver Spring, MD USA
[4] Swedish Med Prod Agcy, Uppsala, Sweden
[5] Arrowhead Pharmaceut Inc, Pasadena, CA USA
来源：
GASTROENTEROLOGY | 2019年 / 156卷 / 03期
关键词：
TENOFOVIR DISOPROXIL FUMARATE; ACUTE EXACERBATION; ANTIVIRAL THERAPY; LAMIVUDINE; FLARES; RISK; CLEARANCE; INFECTION; DRUGS;
D O I：
10.1053/j.gastro.2018.11.062
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：529 / +
页数：9
相关论文
共 47 条
  • [1] [Anonymous], 2010, Notice. Fed. Regist, V75, P3471
  • [2] Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study
    Berg, Thomas
    Simon, Karl-Georg
    Mauss, Stefan
    Schott, Eckart
    Heyne, Renate
    Klass, Dietmar M.
    Eisenbach, Christoph
    Welzel, Tania Mara
    Zachoval, Reinhart
    Felten, Gisela
    Schulze-zur-Wiesch, Julian
    Cornberg, Markus
    Op den Brouw, Marjoleine L.
    Jump, Belinda
    Reiser, Hans
    Gallo, Lothar
    Warger, Tobias
    Petersen, Joerg
    [J]. JOURNAL OF HEPATOLOGY, 2017, 67 (05) : 918 - 924
  • [3] Impact of non-alcoholic fatty liver disease on chronic hepatitis B
    Bondini, Silvia
    Kallman, Jillian
    Wheeler, Angela
    Prakash, Shivaani
    Gramlich, Terry
    Jondle, Daniel M.
    Younossi, Zobair M.
    [J]. LIVER INTERNATIONAL, 2007, 27 (05) : 607 - 611
  • [4] High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C
    Bressler, BL
    Guindi, M
    Tomlinson, G
    Heathcote, J
    [J]. HEPATOLOGY, 2003, 38 (03) : 639 - 644
  • [5] Concordance of sustained virologic response at weeks 4, 12 and 24 post-treatment of hepatitis C in the era of new oral direct-acting antivirals: A concise review
    Burgess, Sarah V.
    Hussaini, Trana
    Yoshida, Eric M.
    [J]. ANNALS OF HEPATOLOGY, 2016, 15 (02) : 154 - 159
  • [6] Hepatitis B flares in chronic hepatitis B: Pathogenesis, natural course, and management
    Chang, Ming-Ling
    Liaw, Yun-Fan
    [J]. JOURNAL OF HEPATOLOGY, 2014, 61 (06) : 1407 - 1417
  • [7] A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
    Chang, TT
    Gish, RG
    de Man, R
    Gadano, A
    Sollano, J
    Chao, YC
    Lok, AS
    Han, KH
    Goodman, Z
    Zhu, J
    Cross, A
    DeHertogh, D
    Wilber, R
    Colonno, R
    Apelian, D
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) : 1001 - 1010
  • [8] When can we stop nucleoside analogues in patients with chronic hepatitis B?
    Chong, Chern Hao
    Lim, Seng Gee
    [J]. LIVER INTERNATIONAL, 2017, 37 : 52 - 58
  • [9] Animal models of HBV infection
    Dandri, Maura
    Petersen, Joerg
    [J]. BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2017, 31 (03) : 273 - 279
  • [10] Drugs in Development for Hepatitis B
    Dawood, Altaf
    Basit, Syed Abdul
    Jayaraj, Mahendran
    Gish, Robert G.
    [J]. DRUGS, 2017, 77 (12) : 1263 - 1280
12345